Qtick
/
Sign in

Novo Nordisk A/S (NVO) Competitors & Peers

The 5 largest companies in the same industry as Novo Nordisk A/S, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.

How we identify peers ↗

TickerRelationshipPriceComparables
LLYCompetitor$1,143.14P/E 38.5RSI 45Cap 1.02 T
JNJPeer$269.38P/E 31.4RSI 55Cap 652.5 B
ABBVPeer$263.93P/E 74.1RSI 59Cap 466.4 B
MRKPeer$146.22P/E 115.1RSI 50Cap 355.0 B
AZNPeer$166.33P/E 24.5RSI 51Cap 253.6 B

How these relationships were derived

Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.

Model-inferred relationships (unverified)

Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.

  • LLYCompetitor

    Novo Nordisk (Ozempic/Wegovy semaglutide) and Eli Lilly (Mounjaro/Zepbound tirzepatide) are the two dominant GLP-1 competitors globally for diabetes and obesity.

    Model-inferred, unverified — treat as a lead, not evidence
  • LLYCompetitor

    Novo Nordisk (Ozempic/Wegovy) is Eli Lilly's primary global competitor in GLP-1 agonist therapies for type 2 diabetes and obesity.

    Model-inferred, unverified — treat as a lead, not evidence
  • WSTCustomer

    West supplies elastomeric closures and cartridge parts for Novo Nordisk's Wegovy/Ozempic injector pens.

    Model-inferred, unverified — treat as a lead, not evidence
  • CATALENTMerger

    Novo Nordisk acquired Catalent's drug product manufacturing plants from Novo Holdings for $11B to secure fill-finish capacity for its semaglutide injectable pipeline.

    Model-inferred, unverified — treat as a lead, not evidence
  • CATALENTPartner

    Novo Nordisk acquired Catalent's drug product manufacturing plants from Novo Holdings for $11B to secure fill-finish capacity for its semaglutide injectable pipeline.

    Model-inferred, unverified — treat as a lead, not evidence
  • CORSupplier

    Cencora is Novo Nordisk's second-largest US wholesale distributor, representing approximately 17% of total global net sales in 2024.

    Model-inferred, unverified — treat as a lead, not evidence
  • HIMSCompetitor

    Novo Nordisk competes with Hims & Hers' weight loss offerings, as Hims & Hers provides access to compounded semaglutide which competes with Novo's Ozempic and Wegovy.

    Model-inferred, unverified — treat as a lead, not evidence
  • MCKSupplier

    McKesson is Novo Nordisk's largest US wholesale distributor, representing approximately 23% of total global net sales in 2024.

    Model-inferred, unverified — treat as a lead, not evidence
  • CAHSupplier

    Cardinal Health is Novo Nordisk's third-largest US wholesale distributor, representing approximately 15% of total global net sales in 2024.

    Model-inferred, unverified — treat as a lead, not evidence
  • VKTXCompetitor

    VK2735 vs Wegovy/Ozempic competition.

    Model-inferred, unverified — treat as a lead, not evidence
  • RYTMCompetitor

    Competes broadly in weight management, though Rhythm targets rare genetic obesity pathways specifically.

    Model-inferred, unverified — treat as a lead, not evidence
  • ASNDCompetitor

    Competes in growth hormone therapy markets, where Novo Nordisk operates Sogroya.

    Model-inferred, unverified — treat as a lead, not evidence
  • AMGNCompetitor

    Amgen's clinical pipeline for metabolic disorders positions it as a key future competitor to Novo Nordisk's Wegovy.

    Model-inferred, unverified — treat as a lead, not evidence
  • CTLTSupplier

    Catalent is a primary CDMO partner for Novo Nordisk providing sterile fill-finish services for Wegovy auto-injectors.

    Model-inferred, unverified — treat as a lead, not evidence
  • YPS.SWSupplier

    Ypsomed has long-term supply agreements to provide Novo Nordisk with auto-injector mechanisms for its growing metabolic portfolio.

    Model-inferred, unverified — treat as a lead, not evidence
  • WSTSupplier

    West Pharmaceutical supplies critical elastomer plungers and seals used in Novo Nordisk's auto-injector pens.

    Model-inferred, unverified — treat as a lead, not evidence
  • ROG.SWCompetitor

    Through its acquisition of Carmot Therapeutics, Roche is developing oral and injectable incretin therapies targeting obesity.

    Model-inferred, unverified — treat as a lead, not evidence
  • PFECompetitor

    Pfizer is developing once-daily oral GLP-1 candidates like danuglipron to challenge the injectable dominance of Novo Nordisk.

    Model-inferred, unverified — treat as a lead, not evidence
  • STVNSupplier

    Novo Nordisk utilizes Stevanato's EZ-fill glass containers for the assembly of its injectable drug delivery systems.

    Model-inferred, unverified — treat as a lead, not evidence
  • TMOSupplier

    Thermo Fisher's CDMO unit assists Novo Nordisk with manufacturing components of the Wegovy supply chain.

    Model-inferred, unverified — treat as a lead, not evidence
  • LONN.SWSupplier

    Lonza has been tapped by major pharmaceutical players including Novo Nordisk to expand fill-finish capacity for GLP-1 therapies.

    Model-inferred, unverified — treat as a lead, not evidence
  • 1SXP.DESupplier

    Schott Pharma supplies pre-fillable glass syringes and cartridges that are integral to Novo Nordisk's injection devices.

    Model-inferred, unverified — treat as a lead, not evidence
  • BDXSupplier

    Becton Dickinson provides specialized injection components for Novo Nordisk's diabetes and obesity care units.

    Model-inferred, unverified — treat as a lead, not evidence